CytomX Therapeutics Inc. (NASDAQ:CTMX) Director Ix L.P. Canaan sold 45,324 shares of the stock in a transaction that occurred on Monday, November 21st. The shares were sold at an average price of $11.61, for a total transaction of $526,211.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ix L.P. Canaan also recently made the following trade(s):

  • On Wednesday, November 16th, Ix L.P. Canaan sold 51,581 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.50, for a total transaction of $593,181.50.
  • On Monday, November 14th, Ix L.P. Canaan sold 86,270 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.16, for a total transaction of $962,773.20.
  • On Wednesday, November 9th, Ix L.P. Canaan sold 13,730 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.03, for a total transaction of $151,441.90.

Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) opened at 11.83 on Tuesday. The stock has a 50 day moving average of $12.53 and a 200 day moving average of $11.69. The stock’s market cap is $430.64 million. CytomX Therapeutics Inc. has a 1-year low of $9.10 and a 1-year high of $24.68.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $117,000. Wells Fargo & Company MN boosted its stake in shares of CytomX Therapeutics by 253.6% in the third quarter. Wells Fargo & Company MN now owns 7,808 shares of the company’s stock valued at $122,000 after buying an additional 5,600 shares during the period. BlackRock Inc. boosted its stake in shares of CytomX Therapeutics by 23.2% in the third quarter. BlackRock Inc. now owns 9,344 shares of the company’s stock valued at $146,000 after buying an additional 1,759 shares during the period. American International Group Inc. boosted its stake in shares of CytomX Therapeutics by 165.7% in the second quarter. American International Group Inc. now owns 11,759 shares of the company’s stock valued at $120,000 after buying an additional 7,333 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in shares of CytomX Therapeutics by 146.8% in the second quarter. Nationwide Fund Advisors now owns 12,925 shares of the company’s stock valued at $132,000 after buying an additional 7,688 shares during the period. Hedge funds and other institutional investors own 52.06% of the company’s stock.

Separately, Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 11th.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

5 Day Chart for NASDAQ:CTMX

Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.